Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
Healthcare
$5.28 +1.70%
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
52W Low $5.31High $29.98
Volume 0.04M
Average 0.06M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$1.12M
FY 2025 · Annual
Investing Cash Flow
-$42,000.00
FY 2025 · Annual
Financing Cash Flow
$13.90M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.58M) | (250.16M) | (113.72M) | 136K | 5.7M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.22M | 25.48M | 34.1M | 20.97M | 10.84M |
| Change in Working Capital | 41.53M | (18.39M) | (58.98M) | (65.51M) | (27.78M) |
| Accounts Receivables | 9.39M | 0 | (8.67M) | (2.07M) | 1.55M |
| Inventory | 0 | 0 | (29.65M) | (33.8M) | 0 |
| Accounts Payables | 9.36M | 2.2M | (11.58M) | (2.94M) | (2.4M) |
| Other Working Capital | 22.78M | (20.59M) | (9.08M) | (26.71M) | (26.93M) |
| Other Non-Cash Items | 4.57M | 7.62M | 15M | (109.68M) | 8.23M |
| Operating Cash Flow | 6.69M | (228.82M) | (117.35M) | (148.61M) | 1.12M |
| Capital Expenditures | (9.57M) | (9.82M) | (7.98M) | (380K) | (252K) |
| Acquisitions (Net) | 0 | (92.25M) | 0 | 0 | 210K |
| Purchases of Investments | (95.97M) | (48.22M) | (4.43M) | 13.52M | 0 |
| Sales of Investments | 169.63M | 140.47M | 22.98M | 142.67M | 0 |
| Other Investing Activities | 0 | 92.25M | 0 | (13.52M) | 0 |
| Investing Cash Flow | 64.09M | 82.43M | 10.58M | 142.29M | (42K) |
| Debt Repayment | (948K) | 25.7M | 50.52M | (127.91M) | 0 |
| Common Stock Issued | 2.13M | 101.17M | 18.16M | 23.53M | 13.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.13M | 2.74M | 3.03M | 14M | 0 |
| Financing Cash Flow | 1.18M | 129.6M | 71.71M | (90.37M) | 13.9M |
| Effect of Forex Changes | (1K) | (1K) | 2K | (1K) | 0 |
| Net Change in Cash | 71.95M | (16.79M) | (35.07M) | (96.69M) | 14.97M |
| Free Cash Flow | (2.88M) | (238.64M) | (125.33M) | (148.99M) | 865K |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$5.7M
+ D&A$4.1M
+ Stock-Based Comp$10.8M
+ Deferred Tax$0
- Working Capital-$27.8M
+ Other Non-Cash$8.2M
= Operating Cash Flow$1.1M
- Capex-$252.0K
= Free Cash Flow$865.0K
Analysis
FY2025 free cash flow is $865.0K. FCF conversion is 15.2% of net income. Operating cash flow was $1.1M, with capex of -$252.0K. The largest bridge item is Working Capital at -$27.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| EFFECT | EFFECT filing | Aug 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 |
Does MCRB generate free cash flow?
Seres Therapeutics, Inc. (MCRB) generated $865,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does MCRB produce?
Operating cash flow was $1.12M, before capital expenditures of $252,000.00.
Continue the stock analysis
Jump to another research area for this company.